GLOBAL NON-OPIOID PAIN TREATMENT MARKET FORECAST 2018-2026

  • You are here:
  • Home
  • Reports
  • GLOBAL NON-OPIOID PAIN TREATMENT MARKET FORECAST 2018-2026

GLOBAL NON-OPIOID PAIN TREATMENT MARKET FORECAST 2018-2026

The Global Non-opioid pain treatment market is anticipated to grow at a CAGR of 16.62% between 2018 and 2026. In pain management, certain classes of drugs have proven to be very effective. Some of these classes are nonsteroidal anti-inflammatory drugs, opioids (which are actually narcotics used for medical treatment), anticonvulsants (anti-epilepsy drugs) and antidepressants. The Non-opioid pain treatment market is primarily driven by the following factors:

GLOBAL NON-OPIOID PAIN TREATMENT MARKET FORECAST 2018-2026

Global Opioid Induced Constipation drug market by Drug Type (Methyl Naltrexone Bromide, Lubiprostone, Naloxegol, Naldemedine, Alvimopan, Dolcanatide, Elobixibat ) by Prescription Type (Prescribed Drugs, Over the Counter Drugs) & by Geography

Request free sample

The Global Non-opioid pain treatment market is anticipated to grow at a CAGR of 16.62% between 2018 and 2026. In pain management, certain classes of drugs have proven to be very effective. Some of these classes are nonsteroidal anti-inflammatory drugs, opioids (which are actually narcotics used for medical treatment), anticonvulsants (anti-epilepsy drugs) and antidepressants. The Non-opioid pain treatment market is primarily driven by the following factors:

  • Growing geriatric population
  • Easy and effective medications of non-opioids drugs for cancer treatment
  • Increased prevalence of migraines
  • Promising pipeline

Global Non-opioid pain treatment marke

To learn more about this report, request a free sample copy

The important drivers increasing growth in the Global Non-opioid pain treatment market are growing geriatric population and easy and effective medications of non-opioids drugs for cancer treatment. Better healthcare facilities and the availability of sophisticated treatment options have improved life expectancy rates worldwide. This has increased the number of older population, which is the largest user of preventive and predictive medication due to their susceptibility to developing diseases because of low immunity levels. Treating cancer pain with medication provides relief from severe chronic pain.

The Therapeutic applications of Non-opioid pain treatment market are used extensively for various purposes. Arthritis treatment is one of the most common indications of non-opioid pain management and, specifically, the cannabis market is experiencing a major uptake in users to control pain for the condition. Neuropathic pain is a prominent form of pain associated with a wide variety of common diseases and conditions, including cancer, diabetes, and others. Cancer treatment is most often accompanied by a considerable amount of pain, although its intensity and duration vary patient-to-patient and depends on the type of cancer, its stage and the treatment provided. Other pain indications include surgical pain, dental pain and others not listed in previous market segments. The use of medical cannabis has reportedly improved pain management for patients suffering from neuropathic pain.

Preference for alternative therapies and counterfeit products are restricting the market growth. Many Non-opioids drugs do not show the required long-term efficacy, which leads to patients opting for non-pharmacologic treatments for pain relief. Counterfeit products are fraudulent products that are deliberately mislabeled in order to trick consumers into thinking that they are genuine products.

The Global Non-opioid pain treatment market segments include products and therapeutic applications.

Products are segmented into:

  • Medical cannabis
  • Menthol-containing
  • Omega 3 fatty acid-containing
  • Botulinum toxins
  • Capsaicin-derived

Therapeutic applications are segmented into:

  • Orthopaedic/musculoskeletal pain
  • Neuropathic pain
  • Cancer pain
  • Other pain

.This report covers the present market conditions and the growth prospects of the Global Non-opioid pain treatments market for 2018-2026 and considered the revenue generated through the sales of Non-opioid pain treatments for Products and Therapeutic applications to calculate the market size by considering 2017 as the base year.

Geographically, the Global Non-opioid pain treatments market has been segmented on the basis of four major regions, which include:

  • North America: The U.S. & Canada
  • Asia-Pacific: China, India, Japan, Australia, South Korea & Rest of APAC
  • Europe: The UK, France, Germany, Italy, Spain, Russia & Rest of Europe
  • Rest of World: Latin America & Middle East and Africa

The Non-opioid pain treatment market in North America is expected to hold the largest share by 2026 owing to the presence of strong pipeline and favourable regulatory scenario. The major driver for this market is the rising prevalence of osteoarthritis in the general populace. The expanded access to medical care due to healthcare reforms further drives the market in the North Americas. Thus, the growing demographics and economies in this region are expected to offer good opportunities for the market. However, the loss of patents of major branded drugs will inhibit the market growth. On the other hand, the Asia-Pacific market is anticipated to be the fastest-growing region for the Non-opioid pain treatment market. The majority of the market is generated in less developed countries with relaxed regulations regarding cannabis. China, Japan, and India are the leading markets for these drugs because of the high demand for better health management and economic conditions and awareness about pain medication. In addition, the growing ageing population in this region will also affect the market positively.

The Non-opioid pain treatment market is segmented on the basis of products which are sub-divided into Medical cannabis, Menthol-containing, Omega 3 fatty acid-containing, Botulinum toxins and Capsaicin-derived. The market for medical cannabis in pain treatment has developed into a large market opportunity and is expected to continue to increase in terms of value over the forecast period. Menthol is the prevailing biological compound which originates in the plant family genre “Mentha”, more frequently identified as peppermint plants and mint. Omega-3 fatty acids are deliberated vital fatty acids. They are essential for human well-being. However, the body cannot make them, and hence they must be obtained through the consumption of food. Botulinum toxin (BTX) is a neurotoxic protein produced by the Clostridium botulinum bacteria. Capsaicin is used as an analgesic in topical ointments, nasal sprays, and dermal patches to relieve pain.

The major market players of the Global Non-opioid pain treatment market are:

  • ALLERGAN PLC
  • AURORA CANNABIS ENTERPRISES INC.
  • CANOPY GROWTH CORP.
  • GW PHARMACEUTICALS
  • TILRAY

Company Profiles covers analysis of important players.

Allergan offers therapies for the relief of symptoms of fibromyalgia with the product Savella (milnacipran) and control of migraines with its diverse Botox (botulinum toxin) product. Tilray functions as one of the world’s utmost progressive medical cannabis production facilities and research, situated in Nanaimo, British Columbia. It adheres to Good Manufacturing Practices (GMP), a system for ensuring that products are manufactured and controlled according to stringent quality standards.

Key Findings of the Global Non-opioid pain treatment market:

  • Medical cannabis holds the largest market share and is anticipated to grow at a faster rate during the forecast period
  • Orthopaedic/musculoskeletal pain is the widely used therapeutic application
  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • MEDICAL CANNABIS HOLDS THE LARGEST MARKET SHARE AND IS ANTICIPATED TO GROW AT A FASTER RATE DURING THE FORECAST PERIOD
      • ORTHOPEDIC/MUSCULOSKELETAL PAIN IS THE WIDELY USED THERAPEUTIC APPLICATION
  1. MARKET DETERMINANTS
    • MARKET DRIVERS
      • GROWING GERIATRIC POPULATION
      • EASY AND EFFECTIVE MEDICATIONS OF NON-OPIOIDS DRUGS FOR CANCER TREATMENT
      • INCREASED PREVALENCE OF MIGRAINES
      • PROMISING PIPELINE
    • MARKET RESTRAINTS
      • PREFERENCE FOR ALTERNATIVE THERAPIES
      • COUNTERFEIT PRODUCTS ARE RESTRICTING THE MARKET GROWTH
    • MARKET OPPORTUNITIES
      • FAVORABLE REGULATORY SCENARIO
      • INCREASE IN AWARENESS OF PAIN MANAGEMENT DRUGS
    • MARKET CHALLENGES
      • SHORT-TERM RELIEF
      • ILLEGAL STATUS OF CANNABIS MADE IT DIFFICULT FOR RESEARCHERS TO STUDY THE PLANT
      • GOVERNMENT RESTRICTIONS
  1. MARKET SEGMENTATION
    • MARKET BY PRODUCTS 2018-2026
      • MEDICAL CANNABIS
      • MENTHOL-CONTAINING
      • OMEGA 3 FATTY ACID-CONTAINING
      • BOTULINUM TOXINS
      • CAPSAICIN-DERIVED
    • MARKET BY THERAPEUTIC APPLICATION 2018-2026
      • ORTHOPEDIC/MUSCULOSKELETAL PAIN
      • NEUROPATHIC PAIN
      • CANCER PAIN
      • OTHER PAIN
  1. KEY ANALYTICAL
    • PORTER’S FIVE FORCES ANALYSIS
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTES
      • BARGAINING POWER OF BUYERS
      • BARGAINING POWER OF SUPPLIERS
      • THREAT OF RIVALRY
    • ETYMOLOGY OF PAIN AND PAIN TREATMENT
    • PATENT ANALYSIS
    • DEVELOPMENTS IN NON-OPIOID PAIN TREATMENT
    • MARKET TRENDS
      • INCREASE IN R&D ACTIVITIES
      • USE OF OFF-LABEL DRUGS
      • GROWING FOCUS ON EMERGING ECONOMIES
    • KEY BUYING CRITERIA
  2. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • GERMANY
      • ITALY
      • FRANCE
      • UNITED KINGDOM
      • SPAIN
      • RUSSIA
      • REST OF EUROPE
    • ASIA PACIFIC
      • CHINA
      • AUSTRALIA
      • JAPAN
      • INDIA
      • SOUTH KOREA
      • REST OF ASIA-PACIFIC
    • REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST AND AFRICA
  1. COMPANY PROFILES
    • ALLERGAN PLC
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • APHRIA
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • AURORA CANNABIS ENTERPRISES INC.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • BEDROCAN
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • CANOPY GROWTH CORP.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • CARA THERAPEUTICS
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • CENTREXION THERAPEUTICS
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • CHT MEDICAL
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
    • CRONOS GROUP
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • GW PHARMACEUTICALS
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • MEDICAL MARIJUANA INC.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • MEDROPHARM GMBH
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
    • TILRAY
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • VANWAY
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO

LIST OF TABLES

TABLE  1      GLOBAL NON-OPIOID PAIN TREATMENT MARKET BY GEOGRAPHY 2018-2026

TABLE  2      PHYSIOLOGICAL EFFECTS OF PAIN

TABLE  3      EXTENDED-RELEASE TRADE NAME INCLUDED IN OPIOID REMS 2017

TABLE  4      EXTENDED-RELEASE GENERIC NAME INCLUDED IN OPIOID REMS 2017

TABLE  5      ADOPTION OF MEDICAL CANNABIS DIFFERENT COUNTRIES 2017 (%)

TABLE  6      GLOBAL NON-OPIOID PAIN TREATMENT MARKET BY PRODUCTS 2018-2026

TABLE  7      GLOBAL NON-OPIOID PAIN TREATMENT MARKET IN MEDICAL CANNABIS BY THERAPEUTIC APPLICATION 2018-2026

TABLE  8      CANNABIS CLINICAL TRIALS FOR PAIN TREATMENT 2017

TABLE  9      GLOBAL NON-OPIOID PAIN TREATMENT MARKET IN MENTHOL-CONTAINING BY THERAPEUTIC APPLICATION 2018-2026

TABLE  10    GLOBAL NON-OPIOID PAIN TREATMENT MARKET IN OMEGA 3 FATTY ACID-CONTAINING BY THERAPEUTIC APPLICATION 2018-2026

TABLE  11    BOTULINUM TOXIN CLINICAL TRIALS FOR PAIN TREATMENT 2017

TABLE  12    GLOBAL NON-OPIOID PAIN TREATMENT MARKET IN BOTULINUM TOXINS BY THERAPEUTIC APPLICATION 2018-2026

TABLE  13    BOTULINUM TOXIN CLINICAL TRIALS FOR PAIN TREATMENT 2017

TABLE  14    GLOBAL NON-OPIOID PAIN TREATMENT MARKET IN CAPSAICIN-DERIVED BY THERAPEUTIC APPLICATION 2018-2026

TABLE  15    CAPSAICIN-DERIVED CLINICAL TRIALS FOR PAIN TREATMENT 2017

TABLE  16    GLOBAL NON-OPIOID PAIN TREATMENT MARKET BY THERAPEUTIC APPLICATION  2018-2026

TABLE  17    GLOBAL NON-OPIOID PAIN TREATMENT MARKET IN ORTHOPEDIC/MUSCULOSKELETAL PAIN BY PRODUCT 2018-2026

TABLE  18    GLOBAL NON-OPIOID PAIN TREATMENT MARKET IN NEUROPATHIC PAIN BY PRODUCT 2018-2026

TABLE  19    GLOBAL NON-OPIOID PAIN TREATMENT MARKET IN CANCER PAIN BY PRODUCT 2018-2026

TABLE  20    GLOBAL NON-OPIOID PAIN TREATMENT MARKET IN OTHER PAIN BY PRODUCT 2018-2026

TABLE  21    MEDICAL CANNABIS PATENTS IN THE U.S. BY TYPE, 2017 (%)

TABLE  22    MEDICAL CANNABIS TECHNOLOGIES PATENTS IN THE U.S. BY TYPE 2017 (%)

TABLE  23    NUMBER OF MEDICAL CANNABIS  PATENTS IN THE UNITED STATES BY COMPANY 2017

TABLE  24    NUMBER OF MEDICAL CANNABIS PATENTS IN THE UNITED STATES 2017

TABLE  25    GLOBAL NON-OPIOID PAIN TREATMENT MARKET BY GEOGRAPHY 2018-2026

TABLE  26    NORTH AMERICA NON-OPIOID PAIN TREATMENT MARKET 2018-2026

TABLE  27    THE UNITED STATES NON-OPIOID PAIN TREATMENT MARKET BY PRODUCT 2018-2026

TABLE  28    THE UNITED STATES NON-OPIOID PAIN TREATMENT MARKET BY THERAPEUTIC APPLICATION 2018-2026

TABLE  29    CANADA NON-OPIOID PAIN TREATMENT MARKET BY PRODUCT 2018-2026

TABLE  30    CANADA NON-OPIOID PAIN TREATMENT MARKET BY THERAPEUTIC APPLICATION 2018-2026

TABLE  31    EUROPE NON-OPIOID PAIN TREATMENT MARKET 2018-2026

TABLE  32    GERMANY NON-OPIOID PAIN TREATMENT MARKET BY PRODUCTS 2018-2026

TABLE  33    GERMANY NON-OPIOID PAIN TREATMENT MARKET BY THERAPEUTIC APPLICATION 2018-2026

TABLE  34    ITALY NON-OPIOID PAIN TREATMENT MARKET BY PRODUCTS 2018-2026

TABLE  35    ITALY NON-OPIOID PAIN TREATMENT MARKET BY THERAPEUTIC APPLICATION 2018-2026

TABLE  36    FRANCE NON-OPIOID PAIN TREATMENT MARKET BY PRODUCTS 2018-2026

TABLE  37    FRANCE NON-OPIOID PAIN TREATMENT MARKET BY THERAPEUTIC APPLICATION 2018-2026

TABLE  38    UNITED KINGDOM NON-OPIOID PAIN TREATMENT MARKET BY PRODUCTS 2018-2026

TABLE  39    UNITED KINGDOM NON-OPIOID PAIN TREATMENT MARKET BY THERAPEUTIC APPLICATION 2018-2026

TABLE  40    SPAIN NON-OPIOID PAIN TREATMENT MARKET BY PRODUCTS 2018-2026

TABLE  41    SPAIN NON-OPIOID PAIN TREATMENT MARKET BY THERAPEUTIC APPLICATION 2018-2026

TABLE  42    RUSSIA NON-OPIOID PAIN TREATMENT MARKET BY PRODUCTS 2018-2026

TABLE  43    RUSSIA NON-OPIOID PAIN TREATMENT MARKET BY THERAPEUTIC APPLICATION 2018-2026

TABLE  44    ASIA PACIFIC NON-OPIOID PAIN TREATMENT MARKET 2018-2026

TABLE  45    CHINA NON-OPIOID PAIN TREATMENT MARKET BY PRODUCTS 2018-2026

TABLE  46    CHINA NON-OPIOID PAIN TREATMENT MARKET BY THERAPEUTIC APPLICATION 2018-2026

TABLE  47    JAPAN NON-OPIOID PAIN TREATMENT MARKET BY PRODUCTS 2018-2026

TABLE  48    JAPAN NON-OPIOID PAIN TREATMENT MARKET BY THERAPEUTIC APPLICATION  2018-2026

TABLE  49    REST OF WORLD NON-OPIOID PAIN TREATMENT MARKET 2018-2026

LIST OF FIGURES

FIGURE  1    GLOBAL NON-OPIOID PAIN TREATMENT MARKET 2018-2026

FIGURE  2    GLOBAL NON-OPIOID PAIN TREATMENT MARKET IN MEDICAL CANNABIS 2018-2026

FIGURE  3    GLOBAL NON-OPIOID PAIN TREATMENT MARKET IN MENTHOL-CONTAINING 2018-2026

FIGURE  4    GLOBAL NON-OPIOID PAIN TREATMENT MARKET IN OMEGA 3 FATTY ACID-CONTAINING 2018-2026

FIGURE  5    GLOBAL NON-OPIOID PAIN TREATMENT MARKET IN BOTULINUM TOXINS 2018-2026

FIGURE  6    GLOBAL NON-OPIOID PAIN TREATMENT MARKET IN CAPSAICIN-DERIVED 2018-2026

FIGURE  7    GLOBAL NON-OPIOID PAIN TREATMENT MARKET IN ORTHOPEDIC/MUSCULOSKELETAL PAIN 2018-2026

FIGURE  8    GLOBAL NON-OPIOID PAIN TREATMENT MARKET IN NEUROPATHIC PAIN 2018-2026

FIGURE  9    GLOBAL NON-OPIOID PAIN TREATMENT MARKET IN CANCER PAIN 2018-2026

FIGURE  10  GLOBAL NON-OPIOID PAIN TREATMENT MARKET IN OTHER PAIN 2018-2026

FIGURE  11  NON-OPIOID PAIN TREATMENTS PATENTS IN THE UNITED STATES BY TYPE 2017 (%)

FIGURE  12  THE UNITED STATES NON-OPIOID PAIN TREATMENT MARKET 2018-2026

FIGURE  13  CANADA NON-OPIOID PAIN TREATMENT MARKET 2018-2026

FIGURE  14  GERMANY NON-OPIOID PAIN TREATMENT MARKET 2018-2026

FIGURE  15  ITALY NON-OPIOID PAIN TREATMENT MARKET 2018-2026

FIGURE  16  FRANCE NON-OPIOID PAIN TREATMENT MARKET 2018-2026

FIGURE  17  UNITED KINGDOM NON-OPIOID PAIN TREATMENT MARKET 2018-2026

FIGURE  18  SPAIN NON-OPIOID PAIN TREATMENT MARKET 2018-2026

FIGURE  19  RUSSIA NON-OPIOID PAIN TREATMENT MARKET 2018-2026

FIGURE  20  REST OF EUROPE NON-OPIOID PAIN TREATMENT MARKET 2018-2026

FIGURE  21  CHINA NON-OPIOID PAIN TREATMENT MARKET 2018-2026

FIGURE  22  AUSTRALIA NON-OPIOID PAIN TREATMENT MARKET 2018-2026

FIGURE  23  JAPAN NON-OPIOID PAIN TREATMENT MARKET 2018-2026

FIGURE  24  INDIA  NON-OPIOID PAIN TREATMENT MARKET 2018-2026

FIGURE  25  SOUTH KOREA NON-OPIOID PAIN TREATMENT MARKET 2018-2026

FIGURE  26  REST OF ASIA-PACIFIC NON-OPIOID PAIN TREATMENT MARKET 2018-2026

FIGURE  27  LATIN AMERICA NON-OPIOID PAIN TREATMENT MARKET 2018-2026

FIGURE  28  MIDDLE EAST AND AFRICA NON-OPIOID PAIN TREATMENT MARKET 2018-2026

  1. MARKET SEGMENTATION
    • MARKET BY PRODUCTS 2018-2026
      • MEDICAL CANNABIS
      • MENTHOL-CONTAINING
      • OMEGA 3 FATTY ACID-CONTAINING
      • BOTULINUM TOXINS
      • CAPSAICIN-DERIVED
    • MARKET BY THERAPEUTIC APPLICATION 2018-2026
      • ORTHOPAEDIC/MUSCULOSKELETAL PAIN
      • NEUROPATHIC PAIN
      • CANCER PAIN
      • OTHER PAIN
  1. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • GERMANY
      • ITALY
      • FRANCE
      • UNITED KINGDOM
      • SPAIN
      • RUSSIA
      • REST OF EUROPE
    • ASIA PACIFIC
      • CHINA
      • AUSTRALIA
      • JAPAN
      • INDIA
      • SOUTH KOREA
      • REST OF ASIA-PACIFIC
    • REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST AND AFRICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now